BIOMAT Database Logo BIOMAT Database Logo

Synthesis and pharmacological evaluation of indolinone derivatives as novel ghrelin receptor antagonists. 2012

Letizia Puleo, and Pietro Marini, and Roberta Avallone, and Marco Zanchet, and Silvio Bandiera, and Marco Baroni, and Tiziano Croci
Sanofi-Midy Research Centre, Exploratory Unit, Sanofi Research, Via G. Sbodio 2, 20134 Milano, Italy. letizia.puleo@sanofi.com

The ghrelin receptor is a G-protein-coupled receptor (GPCR) widely expressed in the brain, stomach and the intestine. It was firstly identified during studies aimed to find synthetic modulators of growth hormone (GH) secretion. GHSR and its endogenous ligand ghrelin were found to be involved in hunger response. Through food intake regulation, they could affect body weight and adiposity. Thus GHSR antagonists rapidly became an attractive target to treat obesity and feeding disorders. In this study we describe the biological properties of new indolinone derivatives identified as a new, chiral class of ghrelin antagonists. Their synthesis as well as the structure-activity relationship will be discussed herein. The in vitro identified compound 14f was a potent GHSR1a antagonist (IC(50) = 7 nM). When tested in vivo, on gastric emptying model, 14f showed an inhibitory intrinsic effect when given alone and it dose dependently inhibited ghrelin stimulation. Compound 14f also reduced food intake stimulated both by fasting condition (high level of endogenous ghrelin) and by icv ghrelin. Moreover this compound improved glucose tolerance in ipGTT test.

UI MeSH Term Description Entries
D007211 Indoles Benzopyrroles with the nitrogen at the number one carbon adjacent to the benzyl portion, in contrast to ISOINDOLES which have the nitrogen away from the six-membered ring.
D008297 Male Males
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004435 Eating The consumption of edible substances. Dietary Intake,Feed Intake,Food Intake,Macronutrient Intake,Micronutrient Intake,Nutrient Intake,Nutritional Intake,Ingestion,Dietary Intakes,Feed Intakes,Intake, Dietary,Intake, Feed,Intake, Food,Intake, Macronutrient,Intake, Micronutrient,Intake, Nutrient,Intake, Nutritional,Macronutrient Intakes,Micronutrient Intakes,Nutrient Intakes,Nutritional Intakes
D005951 Glucose Tolerance Test A test to determine the ability of an individual to maintain HOMEOSTASIS of BLOOD GLUCOSE. It includes measuring blood glucose levels in a fasting state, and at prescribed intervals before and after oral glucose intake (75 or 100 g) or intravenous infusion (0.5 g/kg). Intravenous Glucose Tolerance,Intravenous Glucose Tolerance Test,OGTT,Oral Glucose Tolerance,Oral Glucose Tolerance Test,Glucose Tolerance Tests,Glucose Tolerance, Oral
D006224 Cricetinae A subfamily in the family MURIDAE, comprising the hamsters. Four of the more common genera are Cricetus, CRICETULUS; MESOCRICETUS; and PHODOPUS. Cricetus,Hamsters,Hamster
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships

Related Publications

Letizia Puleo, and Pietro Marini, and Roberta Avallone, and Marco Zanchet, and Silvio Bandiera, and Marco Baroni, and Tiziano Croci
Synthesis and pharmacological evaluation of novel arylpiperazine derivatives as nonsteroidal androgen receptor antagonists.
November 2004, Chemical & pharmaceutical bulletin,
Letizia Puleo, and Pietro Marini, and Roberta Avallone, and Marco Zanchet, and Silvio Bandiera, and Marco Baroni, and Tiziano Croci
Synthesis and pharmacological evaluation of novel heterotricyclic acylhydrazone derivatives, designed as PAF antagonists.
October 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences,
Letizia Puleo, and Pietro Marini, and Roberta Avallone, and Marco Zanchet, and Silvio Bandiera, and Marco Baroni, and Tiziano Croci
Synthesis and pharmacological evaluation of novel fused thiophene derivatives as 5-HT2A receptor antagonists: molecular modeling study.
May 2010, European journal of medicinal chemistry,
Letizia Puleo, and Pietro Marini, and Roberta Avallone, and Marco Zanchet, and Silvio Bandiera, and Marco Baroni, and Tiziano Croci
Synthesis and pharmacological evaluation of coumarin derivatives as cannabinoid receptor antagonists and inverse agonists.
April 2009, Bioorganic & medicinal chemistry,
Letizia Puleo, and Pietro Marini, and Roberta Avallone, and Marco Zanchet, and Silvio Bandiera, and Marco Baroni, and Tiziano Croci
Synthesis and evaluation of novel thiazolidine derivatives as thromboxane A2 receptor antagonists.
March 1994, Chemical & pharmaceutical bulletin,
Letizia Puleo, and Pietro Marini, and Roberta Avallone, and Marco Zanchet, and Silvio Bandiera, and Marco Baroni, and Tiziano Croci
Synthesis and pharmacological evaluation of novel substituted 9-deazaxanthines as A2B receptor antagonists.
July 2010, European journal of medicinal chemistry,
Letizia Puleo, and Pietro Marini, and Roberta Avallone, and Marco Zanchet, and Silvio Bandiera, and Marco Baroni, and Tiziano Croci
Synthesis and pharmacological characterization of novel 6-fluorochroman derivatives as potential 5-HT1A receptor antagonists.
July 1998, Journal of medicinal chemistry,
Letizia Puleo, and Pietro Marini, and Roberta Avallone, and Marco Zanchet, and Silvio Bandiera, and Marco Baroni, and Tiziano Croci
Synthesis and pharmacological evaluation of aryl aminosulfonamide derivatives as potent 5-HT(6) receptor antagonists.
August 2010, Bioorganic & medicinal chemistry letters,
Letizia Puleo, and Pietro Marini, and Roberta Avallone, and Marco Zanchet, and Silvio Bandiera, and Marco Baroni, and Tiziano Croci
Synthesis and pharmacological evaluation of optically pure, novel carbonyl guanidine derivatives as dual 5-HT2B and 5-HT7 receptor antagonists.
November 2014, Bioorganic & medicinal chemistry,
Letizia Puleo, and Pietro Marini, and Roberta Avallone, and Marco Zanchet, and Silvio Bandiera, and Marco Baroni, and Tiziano Croci
Synthesis and cytotoxic evaluation of novel 3-substituted derivatives of 2-indolinone.
January 2012, Iranian journal of pharmaceutical research : IJPR,
Copied contents to your clipboard!